Pfizer to Acquire Wyeth as Lipitor Patent Ends?

Reports indicate that the world’s largest drug-maker, Pfizer, is in direct acquisition talks with competing drug-maker Wyeth. The buy-out could cost as much as $62 billion. Pfizer, the maker of Lipitor, has also been hit hard by the global financial crisis. The company recently announced 15,000 job cuts in a cost cutting move. The company CEO, Jeffrey Kindler, is facing mounting pressure to ensure the company remains competitive as the patent to Lipitor is set to expire in 2011. The cholesterol drug Lipitor has become the world’s best selling drug, earning Pfizer $12 billion in 2007. Many more drug-related patents are set to expire in the coming years, paving the way for competitors to cash in on some of the top medicine in the world. It is believed Pfizer could limit falling profits to about 11% as opposed to about a 23% projected decline in 2011 with the buy-out. If this acquisition occurs, we can expect job cuts simply given how big the acquisition is.

tag TAGS: , ,
Short URL:
b2p Ensure that you follow us on Twitter and Like us on Facebook
Hercules holds a B.Comm Finance from Ryerson University in Toronto, Canada. He is a Chartered Financial Analyst (CFA) level 3 candidate. He was previously a contributor at FiLife, a finance website owned by Dow Jones and IAC. Write to [email protected]
We are perfectly committed to the highest ethical and professional codes of conduct and standards in the industry on a firm wide basis. Learn more about us, our contributors, and our governance
We encourage you to comment. Comments are moderated. Comments that are abusive, off-topic, have marginal substance, or include promotional content will be removed. We cannot facilitate requests to edit or remove comments, or explain moderation decisions

Business 2.0 Press publishes exclusive business tech news and analysis covering start-ups to large-caps from Bay & Wall streets since 2008 from a group of highly knowledgeable industry professionals that abide by the toughest industry codes of conduct and professional standards lightMore

lightAdd value by subscribing (RSS)

logo has the most stock ratios for public companies. Get the most comprehensive micro insight on public firms available on the web, all for free.
Stock Fractionsgo


Colon cancer is one of the leading causes of death. Irrespective of family history, everyone is exposed to the risk. About 90% of colon cancer cases begin from non-cancerous tumors, polyps, which could form in the large bowel. Screening with a colonoscopy will painlessly remove any polyps hence almost entirely reducing your risk of developing the horrible disease. The good news is that about 90% of colon cancer cases are preventable through a simple (yes, simple) colonoscopy.
Learn moreatom
Public service message from Business 2.0 Press